PRESS RELEASE: Syndax Highlighted Late-Stage Programs and Unveil New Pipeline Assets at R&D Event By Admin 16 Jul, 2026
From Discovery to Impact: Dana‑Farber Symposium Highlights Innovations Reshaping Cancer Care By Lisa Ellis 26 Mar, 2026
Dana-Farber Investigators Pinpoint Keys to Cell Therapy Response for Leukemia By Beth Dougherty 15 May, 2025
EGLN1 Protein May be a Possible Therapeutic Target in Rare Kidney Cancer By Beth Dougherty 14 Apr, 2025
Dana-Farber Launches Center for RAS Therapeutics to Target the RAS Oncogene in Cancer By Admin 6 Jan, 2025